This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

PARADIGM - HF sacubutril versus enalapril in heart failure

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

PARADIGM-HF - Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure

  • compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients

  • methodology:
    • double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy
      • primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes
    • inclusion:
      • age >=18 years, NYHA class II, III, or IV symptoms at screening, ejection fraction <= 40% (amended to <=35% December 15th, 2010), plasma B-type natriuretic peptide (BNP) >= 150pg/mL (or N-terminal pro-BNP [NT] proBNP] >=600pg/mL) at screening or hospitalized for HF in the past year and BNP >= 100pg/mL (or NT proBNP >=.400pg/mL)
      • treatment with a stable dose of an ACEI or ARB (equivalent to enalapril>=10mg/day) and beta blocker (unless CI or not tolerated) for >=4 weeks prior to screening was permitted. Use of an aldosterone antagonist >=4 weeks prior to screening was encouraged

  • results:
    • trial was stopped early, according to prespecified rules, after a median follow-up of 27 months, because the boundary for an overwhelming benefit with LCZ696 had been crossed
      • at the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P<0.001)
      • a total of 711 patients (17.0%) receiving LCZ696 and 835 patients (19.8%) receiving enalapril died (hazard ratio for death from any cause, 0.84; 95% CI, 0.76 to 0.93; P<0.001); of these patients, 558 (13.3%) and 693 (16.5%), respectively, died from cardiovascular causes (hazard ratio, 0.80; 95% CI, 0.71 to 0.89; P<0.001)
      • compared with enalapril, LCZ696 also reduced the risk of hospitalization for heart failure by 21% (P<0.001) and decreased the symptoms and physical limitations of heart failure (P=0.001)
      • LCZ696 group had higher proportions of patients with hypotension and nonserious angioedema but lower proportions with renal impairment, hyperkalemia, and cough than the enalapril group

  • conclusion:
    • In PARADIGM-HF, clinically stable patients with heart failure (HF) on conventional HF therapy and who were treated with LCZ696 had:
      • a lower risk of cardiovascular death and 1st hospitalization for worsening HF (ARR 4.7%, NNT=21/2.25 years),
      • but - more symptomatic hypotension (ARI 4.8%, NNH=21; SBP<90mmHg ARI 1.3%, NNH=77) and non-serious angioedema (n=19 vs 10, NS)

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.